March 7, 2024 11:15 AM EST

Ultimovacs' melanoma vaccine fails in PhII; Regenxbio’s $140M offering

Plus, news about MindMed, Ventyx Biosciences, Rakuten Medical and Ross Acquisition Corp:

Ultimovacs’ melanoma vaccine flops in PhII: When added to Bristol Myers Squibb’s Yervoy …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ul­ti­movac­s' melanoma vac­cine fails in PhII; Re­genxbio’s $140M of­fer­ing